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In this presentation, I want to jump back and 
forth between the topic of human genetics and 
the notion that gene-environment interactions 
control our responses to stressors in the 
environment, so far as this relates to human 
health and disease. I also want to spend time at 
the end discussing my views on the risks and 
benefits of information from this kind of 
research.  With its profound implications for 
health disparities, I think this research is 
especially important for this group, for this 
symposium, and for the nation, and I very much 
applaud the organizers of the symposium for 
addressing the subject in such a robust and 
effective way.  
 
As we can tell from cover stories in several 
national publications and other widespread 
media coverage, genetics and genomics are here, 
they’re here to stay, and they are certainly in the 
public’s consciousness.  It seems as though 
every week there is a new headline trumpeting 
the identification of a new gene – genes for 
breast cancer, for intelligence, for just about 
every human disease or quality. While some of 
that publicity is exaggerated, the media coverage 
is useful in informing us that a genetic age is 
upon us.  We’ve made a remarkable amount of 
progress in recent years, but human genetics is 
still a new area, a topic with a whole new set of 
definitions, and a topic with a whole new set of 
policy and health disparity concerns. 
 
Let’s first define some of our terms. What is a 
gene? A gene is the functional or physical unit 
of heredity within our DNA. All living 
organisms, of course, have genes and have DNA 
responsible for heredity.  Genetics is the study of 
the science of heredity, and it has been around 
for a long time.  Genome refers to the complete 
DNA sequence within an organism, that is, 
every single base pair for the entire unit of 
heredity. Genomics is actually a new field in 
biomedical research, developed just recently, 
and founded on advances in discoveries of the 
actual sequences of genomic DNA in various 
organisms. And, the filed of genomics is making 
use of this information in a variety of ways. 
Genomics is the study of complete sets of genes 
– their expression, output, and interactions. 
What one often can see in the scientific literature 
nowadays is the five-letter term, “-omics” that 
refers to analysis making use of information 
from the entire or whole genome.  We now have 
fields called proteomics, metabolomics, 
transcriptomics, and many more –omics 
sciences. These analyses extend to DNA, to 
proteins, and to all sorts of components within 
cells, and are referred to by this blanket term, “-
omics” Sciences. 
 
Let’s look at some of the key milestones for how 
the history of molecular genetics fits together 
and how it emerged into where we stand today – 
involving a huge increase in the size of the DNA 
databases (Figure 1). 
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Figure 1 
Timeline of key molecular genetics discoveries. 
 
 
The development of today’s genomics really 
began with the original discovery in 1944 that 
DNA is the hereditary material. In 1953, there’s 
the famous Watson/Crick double helix 
discovery, and in 1964, Marshall Nirenberg and 
his colleagues working at the intramural 
program at the NIH discovered the genetic code, 
along with several other laboratories. The next 
four items in Figure 1 are basically technology 
development – technologies that enabled us to 
understand the information that we’re going to 
look at in more detail shortly. The discovery of 
expressed sequence tags in 1996 by Venter 
actually drove the sequencing of the human 
genome. And then in 1995 and 1996, we saw the 
first examples of the complete sequencing of a 
eukaryotic genome (that is, an organism with a 
nucleus) – that was in yeast. This sequencing of 
the yeast genome produced a tremendous 
explosion of discovery throughout biology, with 
the subsequent sequencing of many other 
organism’s genomes. It led many people in the 
field to believe that if we could just get the 
human genome sequenced, then we would be 
able to make fundamental advances in human 
health and disease. In 2002, as you are probably 
aware, this was achieved, with the report of a 
draft version of the human genome. Now we 
have a much more refined sequence of an 
example of the human genome. 
 
This sequencing explosion has led to the 
accumulation of a vast amount of information in 
DNA databases. Figure 2 shows an example. Up 
to 2001, as you can see, there was an 
exponential increase in DNA base pair and gene 
sequence information in the database. Many of 
us in biomedical research were successful in 
cloning genes by the now old-fashioned 
techniques in the early to mid-1980s. But, you 
can see that at that point in time, even though we 
thought we already had a lot of sequence 
information, it was almost nothing on the scale 
of what we have today. This chart only displays 
the growth in information up to 2001, and of 
course the curve has gone up tremendously since 
then. 
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Figure 2 
Growth of GenBank 
 
 
 
What can we do with this DNA sequence 
information? Here’s one example (Figure 3) for 
the human genome. 
 
Figure 3 shows the identification of the gene 
types for the various genes in the human 
genome. Looking at this pie chart, you can see 
some of the identified components, such as the 
nucleic acid enzymes, the DNA polymerases, 
the RNA polymerases, DNA ligases, and so on. 
The pie chart also is good news for all of us in 
medical research: It means that the molecular 
function of ~36% of the genome is yet to be 
discovered. 
 
 
 
 
Figure 3 
Identification of gene types in the human genome 
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As you can see in Figure 4, the availability of 
DNA sequence information has stimulated a 
huge amount of new activity in biomedical 
science. We now have functional genomics, the 
study of what DNA actually does in the cell, 
human polymorphism studies or the study of 
genetic variations, comparative genomics, where 
we study genomic differences between species 
to shed light on human characteristics, 
informatics, the use of high-powered computing 
and statistical analysis to mine useful 
information from the DNA sequences, and 
evolutionary genomics, where we try to link 
different origins in the evolutionary trees. 
Further down, you can see that the DNA 
sequence databases also contribute directly to 
global expression studies, which we’ll look at in 
more detail shortly. These studies are the basis 
of the so-called “-omics” sciences such as 
proteomics, which includes the search for 
biomarkers of disease through studies of protein 
expression. Experiments and assays in the -
omics sciences often make use of very high 
throughput technology equipment such as DNA 
microarrays, which can run literally thousands of 
automated experiments on a single plate. All of 
these new sciences are developing quite rapidly; 
they all tie in together at some level, and it won’t 
be long before we see their impact entering 
routine medical practice. 
 
 
 
 
Figure 4 
Availability of DNA sequence information has stimulated new activity in 
biomedical science 
 
 
 
Let’s look more closely at comparative 
genomics. Venter et al. published an excellent 
definition of this important field in Science in 
2001. They defined comparative genomics to be 
the “distribution of the molecular functions in 
“orthologs” conserved between humans and all 
other life forms – orthologs being genes that 
evolved from the same ancestral locus. This 
simply means that the same type of gene occurs 
in other life forms, so therefore one can study, 
for example, bacterial viruses, bacteria, or 
plants, or other forms of animals, in order to 
identify the genes and understand what their 
function might be in higher organisms such as 
humans. 
 
Figure 5 gives us a picture of what we know 
about the numbers of genes in different 
organisms. In the human genome, we have about 
20,000 different genes. As I mentioned earlier, 
36% of the human genome is not yet 
characterized with regard to gene content, so this 
number of genes (20,000) is a moving target.  In 
the mouse genome, it’s about the same situation. 
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The yeast genome has about 6,000 genes. E. 
coli, the classical molecular biology tool, has 
about 4,000 genes. And of course, there are the 
viruses that we’ve used so productively in 
biomedical research. For example, T4, probably 
the most famous of these, has 200 genes. 
Influenza viruses, all of these really small 
viruses known as RNA viruses, have a very 
limited number of genes – only 12. These 
viruses actually make use of the cellular genome 
in order to achieve replication. What this all 
means is that in comparative genomics, we can 
look at yeast and some of these other simple 
organisms and understand functional aspects that 
apply to humans, and also to experimental 
animals. 
 
 
 
Genes in Different Organisms
Yeast ~ 6200 genes      E. coli ~ 4200 genes 
Human ~ 20,000 genes       Mouse ~  20,000 genes
Phage T4 ~ 200 genes
Influenza
~ 12 genes
 
 
Figure 5 
Numbers of genes in different organisms 
 
 
 
Looking back at Figure 4, I want to return in 
more depth to this topic of human 
polymorphisms, because this is the essence of 
what I want to talk about and focus on today. To 
define what a polymorphism is, brings us to a 
really fundamental question: “Is genomics 
important for understanding human health and 
disease?” I can tell you straight away that “yes, 
it is very, important.” 
 
Here is one of the reasons: Genomics allows us 
to attempt to answer the question, “Why does 
one person get a disease while another person 
remains healthy?” We all see our neighbors who 
smoke ten packs of cigarettes a day and never 
have any kind of health impact from it, and then 
others who smoke just rarely who come down 
with lung cancer or other kinds of health 
impacts. Clearly, there is individual 
susceptibility at play as to whether or not we get 
sick, and this relates fundamentally to these 
polymorphisms, or genetic variations among 
individuals.   
 
Individuals differ genetically, and this largely is 
manifested in these DNA polymorphisms.  
Individuals have different behaviors, of course, 
and consume different foods, and are exposed to 
different toxicants and different forms of stress 
from the environment.  This complex, variable 
array of environmental factors combines in 
various ways with complex, variable genetic 
factors to cause every common disease. That’s 
what we call gene-environment interaction. And 
 151
S. H. Wilson / Californian Journal of Health Promotion 2007, Volume 5, Special Issue (Hlth Disparities & Soc Justice), 147-163 
 
these individual differences in environmental 
exposures and genes also result in differences in 
individual susceptibility to disease. So the 
person who smokes a great deal but remains 
healthy and the person who smokes rarely but 
gets lung cancer have different susceptibilities to 
the effects of exposure to cigarette smoke. 
 
There are differences in the genes that control 
our responses to environmental factors. These 
are DNA variations, variations in the sequence 
of DNA, comparing one person to the next. The 
variations are largely (but not exclusively) called 
SNPs, which is our shorthand for single 
nucleotide polymorphism. Let’s look at what 
these SNPs are, and why they’re so vitally 
important to our understanding of human health 
and disease. 
 
A SNP is a nucleotide position that varies from 
one person to another. In the analogy we often 
use, where the gene is the book of life, a SNP a 
spelling error, a typo. It’s a one-letter variation 
from person to person. Sometimes they’re 
harmless, sometimes they’re helpful, and 
sometimes they’re extremely damaging. 
 
The human genome has, on average, one SNP 
per 1,000 base pairs (to be defined below). Most 
of our relatively small genes are in the size range 
of 30,000-40,000 base pairs. So, at one SNP per 
1,000 base pairs, we would have 30-40 SNPs 
present, even in a relatively small gene. Multiply 
that number by the thousands of genes in the 
human genome, and you can start to appreciate 
that we differ from one to another in DNA 
sequence by quite a bit, by virtue of these single 
nucleotide polymorphisms or SNPs. 
 
Genomics allows us to study how individual 
gene variation or polymorphism influences 
susceptibility to disease. Let’s look in a little bit 
more detail now by taking a short primer on 
what these SNPs really are, because I want you 
to understand these concepts of the genetic code, 
how we can all be very active and vigorous 
human beings, but at the same time have 
differences in our genetic code, one individual to 
the next. 
 
This cartoon (Figure 6) emphasizes that in the 
nucleus of our cells, we have the genomic DNA, 
which acts as the instruction book for how the 
cell performs, and in complex organisms like 
human beings, for how the body performs. DNA 
is illustrated here as the famous Watson-Crick 
double helix with each nucleotide base paired 
with its complementary base, A opposite T and 
G opposite C. These combinations are called 
“base pairs.” So how does all of this information 
flow work? 
 
 
 
 
Figure 6 
A cartoon reflecting the genomic DNA 
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As depicted in Figure 7, the DNA instruction 
book sends information from the nucleus out 
into the cytoplasm of the cell where the function 
takes place, as seen in the yellow area of the 
illustration. This happens through what we call 
messenger RNA, which transfers the 
information to the cytoplasm. The messenger 
RNA is then translated into proteins that are 
activated and perform functions in the cell. Of 
course, some of these proteins leak out of the 
cell and float around in the blood and do various 
things, and some of them actually talk to cells 
that are right next to this cell, in order to control 
growth and differentiation in tissues. 
 
 
 
 
 
Figure 7 
DNA instruction book sends information from the nucleus out into the 
cytoplasm 
 
 
 
Here’s another model of the same thing. What 
we’re seeing in green here in Figure 8 is the cell 
nucleus with the DNA inside, all wrapped up 
into packages called chromosomes. If you were 
to take a pair of tweezers and stretch out the 
DNA, it would be a long, linear molecule of 
base pairs. DNA is packaged up into chromatin, 
and into individual chromosomes. You’ve all 
seen this illustration of a chromosome or heard 
about it. But again, lets picture going into the 
chromosome and grasping the DNA with 
tweezers and then stretching out the DNA 
completely. You can see that we come out with 
these pairs of two nucleotides on opposite 
strands, represented by the letters, A, C, G, and 
T. A pairs with T, and C pairs with G – this is 
termed a base pair. 
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Figure 8 
The cell nucleus with DNS inside, all wrapped into packages 
called chromosomes 
 
 
 
Figure 9 illustrates an example of a single 
nucleotide polymorphism, or SNP on one strand 
of DNA. Let’s say on the left we have the 
common situation on a chromosome, where the 
sequence top to bottom is CGACT (note that for 
simplicity, this image does not include that these 
bases are paired with the complementary base on 
the other strand of DNA)., But then, in some 
human beings, this C shown in the box is 
changed to G, so that the sequence now is 
CGAGT, as shown on the right-hand side. This 
is what we’re talking about when we use this 
term single nucleotide polymorphism or SNP. 
Again, why is this important? Let’s look at a few 
more simple cartoons to see why. 
 
 
 
T
C
A
G
G
T
C
A
G
C SNP
 
 
Figure 9 
An example of a single nucleotide polymorphism, or SNP on one 
strand of DNA 
 
 
 
Remember that I told you that the DNA 
instructions are transcribed into messenger 
RNA.  Here’s an example (Figure 10) where the 
DNA actually contains the genetic information, 
right here in this cart. As you can see, the 
messenger RNA has a code. In this case, it’s 
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ACGT. The messenger then transfers the code, 
the ACGT, to the protein factory in the 
cytoplasm (Figure 11), and then the protein is 
made (Figure 12). Generally, the protein is 
engineered to be very strong and active.
 
 
 
 
 
 
 
But what happens if we have a polymorphism, a 
SNP, so that the sequence is CCGT instead of 
ACGT (Figure 13)? In this case, the messenger 
doesn’t really know that there’s anything askew 
here, and takes the message into the protein 
factory (Figure 14). And lo and behold, what 
happens is we get a puny protein out on the 
other side (Figure 15). The small puny protein is 
not able to accomplish its function as well as the 
big strong protein, and eventually the cell 
suffers, especially if stressed. This is the idea of 
the significance of the single nucleotide 
polymorphism. 
 
 
 
  
 
Figure 10 
DNA actually contains the genetic 
information 
 
Figure 11 
The messenger RNA then transfers the 
code, the ACGT, to the protein factory in 
the cytoplasm 
  
  
 
 
Figure 12 
Protein is made 
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Figure 13 
Misspelling of DNA 
 
Figure 14 
The RNA messenger then transfers the misspelled 
code, ACTG, to the protein factory in the 
cytoplasm 
  
  
 
 
Figure 15 
A glitch in protein 
 
 
 
Now let’s introduce another important concept 
in human genetics called linkage disequilibrium 
(Figure 16). This is a genetic term that has to do 
with the prediction that if two markers on a 
piece of DNA, let’s say the yellow asterisk and 
any of the brown dots, are not linked, then there 
will be complete equilibrium in the genome 
between these markers. With equilibrium, you 
would find no examples where the brown dots 
would be linked in the same piece of DNA to the 
asterisks. But, on the other hand, if there is 
linkage disequilibrium, then all of these markers 
will be found together on the same piece of 
DNA. Lets say the brown dots and the asterisk 
represent single nucleotide polymorphisms, and 
that these five polymorphisms are close together 
in one piece of DNA in an ancestral 
chromosome. If the asterisk is associated with 
one or more of the brown spots in a present day 
chromosome, then these SNPs are considered to 
be in linkage disequilibrium. The presence and 
extent of linked markers in the human genome is 
an important discovery that has come out in the 
last few years – i.e., that the genome has blocks 
or units of DNA allowing markers such as SNPs 
to be in linkage disequilibrium. 
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Figure 17 shows us an example of actual results 
that can be obtained when we map single 
nucleotide polymorphisms in human beings. 
These results are from an important signaling 
gene called interleukin-6, and on the left you can 
see an example of what is found with the 
detection of six of the SNPs in this gene (the 
overall gene has 49 SNPs). Reading across the 
top, we have the identification numbers for the 
six SNPs. Reading vertically, we have the 
identification codes for a number of individuals 
– the matrix gives an actual representation of the 
genotyping measurements or data regarding their 
individual SNPs. What we can see right away in 
this so-called Visual Genotype is that the SNPs 
vary quite a bit in these individuals. The blue 
boxes mean that the individual has the common, 
“normal” base pair on both chromosomes – 
that’s called homozygous.  The red boxes mean 
the individual carries the normal base pair on 
one chromosome, but has a different base pair 
on the other chromosome – we call that 
heterozygous. As you can see, most of the boxes 
are blue, because most of us have the 
predominant or common base pair, while a few 
of us have a different base pair. There are some 
individuals who have the common base pair 
corresponding to all six SNPs, with six blue 
boxes reading across from left to right. 
 
In some cases, the DNA information is missing, 
indicating that the analysis didn’t work. 
(Technical challenges are a factor in genotyping 
science, also.) And, in some very rare cases, 
both of the chromosomes have a SNP.  We don’t 
see an example of this in the graphic showing 
the six SNPs. But, when we look over to the 
complete set of 49 SNPs, on the right-hand side, 
a couple of new points are readily apparent, 
including yellow boxes. 
 
 
 
 
Linkage Disequilibrium (Association between Sites)
Ancestral Chromosome
Present-day 
Chromosomes
Linkage disequilibrium generally decreases with 
distance partly due to recombination.
 
 
Figure 16 
Linkage disequilibrium generally descreases with distance partly due to 
recombination 
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Interleukin 6 Gene
Direct - 6 SNPs Complete - 49 SNPs
**
African-
American
41 SNPs
European-
American
29 SNPs
- Homozygote common allele
- Homozygote rare allele
- Heterozygote
- Missing
Visual
Genotypes
 
 
Figure 17 
Interleukin 6 gene 
 
 
 
First of all, as we look at the patterns for each 
individual, we can see that almost none of them 
are identical. This is to be expected – we’re all 
different with regard to this type of analysis. 
Looking on the right-hand side of this panel, you 
can see that the investigators attempted to 
subgroup or stratify the identification of their 
study cohort into African-American individuals 
and European-American individuals. You can 
see that there are general differences between 
those two groups, for the individuals included in 
this particular study. 
 
Now let’s look in a little more detail with these 
data at this issue of linkage disequilibrium 
(Figure 18). Can any of the SNPs we see here on 
the left actually be placed in a linkage 
disequilibrium pattern, so that all of the SNPs 
segregate together? Yes, it does look like there 
are patterns here in the left-hand panel, and in 
the analysis shown in the right-hand panel, the 
investigators clumped the data together into 
patterns. In this analysis, you can see that there 
are some homozygous SNPs, shown in yellow, 
where both of the chromosomes have the base 
pair or SNP that is rare in the general 
population. The red boxes again show that many 
of the individuals have a SNP on one 
chromosome but not on the other. There are 
some examples where the data were not clear 
(grey). But, the other feature we see is that some 
of the individuals are similar. Once again, the 
classification or stratification as African-
American and European-American is done on 
this slide. Obviously, there are some general 
pattern-level differences for these two groups in 
this study. 
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Common Variants - LD Patterns
All  SNPs
African-
American
European-
American
 
 
Figure 18 
Common variants – LD patterns 
 
 
 
Let’s switch gears now and move into the area 
of environmental exposure and risk of disease. 
Now that we’ve learned about genetic factors, 
I’d like to introduce the concept of 
environmental exposures combining with 
genetic susceptibility to produce the bulk of risk 
for the common diseases. 
 
Figure 19 illustrates that common diseases (the 
orange oval) result from the overlap of genetic 
and exposure to environmental factors; the 
greater the contribution to the health burden in 
the population due to common diseases the 
darker the color in the two larger ovals 
representing genetic factors (in red) and 
exposure (in blue). As shown environmental 
factors are broadly defined. The very strong 
genetic factors acting alone, account for a very 
small portion of disease in and of themselves as 
illustrated in light red on the left-hand aspect of 
the red oval in the graphic. So, for example, the 
strong genetic diseases like Huntington’s disease 
represent a small portion of the overall public 
health burden. Most forms of cancer and the 
other common diseases would be in the 
overlapping central orange oval, because these 
diseases arise from a combination of genetic 
factors and environmental exposures. 
 
In the case of environmental exposures, today, 
fortunately, most of the extremely toxic 
occupational exposures have been eliminated. 
For example, here in the U.S. we no longer have 
strong benzene exposures in the workplace or in 
our general environment.  Hence, the amount of 
public health burden from acute toxicity due to 
exposure to environmental hazards alone is only 
modest. The major public health burden is in the 
middle, where exposure to environmental factors 
overlaps with genetic factors to explain common 
disease. 
 
What do we mean by environmental factors? As 
you can see in Figure 19, in our view of the field 
of environmental health sciences we include 
standard items like toxicants, that is, man-made 
chemicals, and toxins, but we also include 
socioeconomic stress and other forms of stress, 
diet, medicines, lifestyle, and infectious disease 
history. So, the definition of environmental 
factors is broad.  
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Environmental Exposure 
and Risk of Disease 
• Environmental Factors/Age
• Genetic Factors
• Most likely as a “Gene-
Environment Interaction” Exposure
Genetic Factors
Disease
Life style; Infectious diseases;
Toxicants; Stress; Radiation;
Medicines; Diet; SES; others.
 
 
Figure 19 
Environmental exposure and risk of disease 
 
 
 
What this diagram really means is that the 
exposure situation alone cannot be tracked to the 
major public health burden from common 
diseases. And, the same point is true with the 
genetic factors or SNPs. But, the specific 
combination of an exposure plus a certain 
genetic variation leads to an increase in risk of 
disease. The effect, in many if not most cases, is 
specific to the kind of exposure and the kind of 
SNP. 
 
It’s easy to understand this latter point: Let’s 
consider the DNA protective capacity known as 
DNA repair, where we know there are several 
different types of DNA repair pathways in our 
cells that don’t overlap functionally. For 
example, when you’re out in the sun and are 
exposed to UV light, you get a type of DNA 
damage in skin that is repaired by a certain 
repair pathway; if you have exposure to UV 
light and also have a SNP that inactivates this 
dedicated repair pathway, then this will lead to 
mutations and eventually to skin cancer. On the 
other hand, if you do not have a SNP in this 
repair pathway, the same sun exposure will be 
harmless. So, in this example, the combination 
of a specific type of stressful exposure and a 
deficiency in the specific cellular pathway for 
protecting against that exposure are key; this 
type of combination situation is the essence of 
the gene-by-environment or gene-environment 
interaction concept in understanding causes of 
common human diseases. 
 
There are already many examples in the 
literature from molecular epidemiology studies 
where a gene-environment interaction is 
necessary to observe a higher adverse risk.  Just 
one example is with several SNPs in the XRCC1 
DNA repair gene combined with cigarette 
smoking; this combination has been associated 
with an increased or decreased risk of cancer, 
depending on the SNP. 
 
What are the future directions in this field of 
gene-environment interactions? The science of 
using alternate experimental models, especially 
animal models and mammalian cell models 
containing or representing the human SNPs is a 
huge opportunity. We will also see more 
comparative genomics, i.e., use of alternate 
experimental systems, where we can identify 
what the functional significance of a SNP is, by 
virtue of studying other systems and comparing 
them to the human situation.  Structural biology 
will also expand our information, where we will 
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analyze atomic level structures to learn what’s 
wrong with a protein that contains a SNP. Of 
course, in vitro studies such as enzyme assays 
and the reconstitution of biological pathways 
will also be important.  All of these areas will 
yield useful new knowledge, but the topic I want 
to focus on now is one you’re going to hear a lot 
about in the future: Whole genome association, 
which is becoming the cornerstone of disease 
susceptibility research. 
 
In the current issue of Nature Genetics, you can 
find papers on whole genome association, where 
SNPs spanning the entire genome have been 
probed. In such studies, one is able to ask the 
question, “Is there any correlation between a 
disease and a SNP or SNP pattern?” The answer, 
of course, is” yes,” such correlations are being 
found.  For example, it’s was reported that there 
are five SNPs associated with a form macular 
degeneration. But, if all five of them are not 
considered as a unit in the analysis, the 
association broke down. Thus, this common 
condition appeared toappeared to be a 
multigenic effect discovered through whole 
genome association research. This type of 
information is developed in the scientific field 
called molecular epidemiology. It is a field that 
makes use of a combination of genetics and 
genomics research with epidemiology. This 
approach is how we’re going to make big 
advances in the future and get wonderful 
surprises, as to genetic associations with disease 
as a function of environmental exposures. 
 
So far in this talk, we’ve seen that we’re in a 
new age of genomics, where there are many new 
technologies such as whole genome association 
and new environmental technologies, as well, to 
give us better precision, to open up windows that 
we never before could see through. As I said 
above, there are many examples now where 
combinations of a genetic variation (SNP) and 
exposure to an environmental factor have been 
found to impact human health. We are, indeed, 
in a new gene by environment age, and this will 
pose new challenges for all of us. 
 
Again, where is all of this going? Obviously, we 
will eventually be able to individualize disease 
risk assignments based on our SNPs and our 
environmental exposures, and use that 
information for prevention, diagnosis, and 
therapy. This information is going to enhance 
the efficiency of therapeutics and of safety 
assessment for preventing exposure and disease.  
It’s going to enhance the efficiency with which 
we can do toxicity assessment. For example, if 
you want to know whether your water contains 
arsenic, this kind of hazard assessment can be 
vastly improved with the new –omics 
technologies.  But the point I really want focus 
on now is that we need better policies for 
protection of individual privacy and dignity, so 
that we can actually make full use of this new 
the omics-based opportunities to protect the 
environment, improve human health, and better 
prevent and treat disease.   
 
What is the timeline on use of omics 
technologies to improve human health?  One can 
hear a lot these days about individualized 
medicine and so on, and individualized risk 
assessment. But actually, even with the 
explosion in the omics sciences, it will be a long 
time before we can routinely reduce the new 
science to practice in the doctor’s offices and 
hospitals and clinics. Yet, better efficiency in 
drug design and in drug safety assessment will 
probably be with us within the next several 
years. Better efficiency in toxicity assessment is 
also feasible and is probably five years away. 
What about better policies? We need these right 
away, right now, in order to protect the science 
and to protect society. 
 
We face many new challenges with this new 
omics science. For example: How do we better 
understand ways to apply the new science to 
improve health for everyone? What approaches 
can we take toward educating ourselves about 
the pros and cons of genomics? What new 
policies do we need? And, how do we develop 
the information and policies without offending 
stakeholders? How do we provide equal and 
appropriate access? As this new science 
emerges, these topics must be addressed, 
because the science will not be allowed to 
realize its full potential to improve human health 
if we don’t address them. 
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Let’s look at just one example. I’ve talked about 
the Human Genome Project – a tremendous 
success in biomedical research applying around 
the world, and in addition there is the Haplotype 
Map program. This involves a mapping of SNPs 
across the entire genome. This advance means 
that in the near future there could be a form or 
version of your SNP genotype in a database. 
And mine too. All of us may have our SNPs 
filed in databases in the near future. We’re going 
to be able to examine disease associations in 
individuals by making use of these SNP patterns 
or whole genome associations, and we are going 
to discover all sorts of new things that we 
haven’t appreciated in the past, as to genetic and 
environmental factors in disease risk. We are 
eventually going to be able to do this with 
measurement of specific SNPs that will allow 
routine screening in clinical laboratories and 
commercial laboratories across the country and 
around the world.  
 
As I see it, there are two big challenges I’d like 
to call your attention to. One: who will be left 
out in the application of this revolutionary 
analysis? If we leave certain people out, then it’s 
just not going to work; it’s not going to be 
appropriate. There’s a need for health disparities 
and other awareness, to make sure we can apply 
this new science appropriately and evenly. The 
second challenge I am concerned about is DNA-
based “labeling” of individuals and groups. It is 
a common practice in the research community to 
stratify or lump individuals into racial groups, 
and then at the same time to associate that 
information with DNA analyses. I have concerns 
about this approach, because I think it could lead 
to just another form of labeling. We’re all 
individually different in our SNPs and in our 
genotypes and in our exposures, and there’s 
reason to allow SNP analysis to become 
transformed into a way of harmful labeling. 
 
How can we better understand and apply this 
new science and move beyond these concerns I 
just mentioned? What are some of the other 
concerns? For example, what are the approaches 
we need to take – and I think it’s up to us to do 
this – to educate the general community about 
the new science? What new public policies, laws 
and guidelines do we need? How do we avoid 
doing harm? At the same time, how do we 
promote widespread and robust use of these new 
tools? 
 
There are many policy issues to be dealt with in 
the near future as the new science emerges. First 
of all, we need good solid ways of obtaining 
informed consent. Obviously, in doing the whole 
genome associations that I’ve discussed, 
scientists need to have informed consent in order 
to look at your DNA and mine. Thus, when the 
information goes into a database, there needs to 
be an informed consent process as to the privacy 
and use of that information. Also, we must have 
community involvement in understanding and 
prioritizing the research. We need to work on 
this a lot. We need to fill the gaps in 
communication of information to the public. 
Many people in the general public are not aware 
of much of the information I’ve discussed in this 
presentation, and we need to learn how to 
communicate these concepts much more 
effectively. Conflict of interest is another 
important issue. For example, what if doctors 
working on this topic own stock in companies 
that market genomics products and recommend 
the products to their patients? This is just one 
example among many of potential conflict of 
interest problems. We must find ways to avoid 
these problems. In both our research and our 
communications efforts, we need to maintain an 
awareness of cultural issues. And we need to be 
diligent in ensuring that people’s expectations 
are realistic and appropriate regarding outcome 
and follow up for this new type of gene-
environment information. Again, the key factor 
is communication. Finally, we need a formal 
process for policy development to protect and 
enable this research. 
 
These issues regarding policy raise a variety of 
concerns.  Again, perhaps the most important is 
the protection of privacy and confidentiality 
within the genetic and genomic databases and 
with truly informed consent. That will be crucial 
to protect us all against adverse use of the 
information. For example, once our 
susceptibilities are known, what will prevent 
discrimination in the workplace, by employers 
or insurance companies or health care providers? 
Another concern is that we will require 
 162
S. H. Wilson / Californian Journal of Health Promotion 2007, Volume 5, Special Issue (Hlth Disparities & Soc Justice), 147-163 
 
protection against “transfer of responsibility” 
because of knowledge about SNPs. What do I 
mean by this? At the moment, it is the 
responsibility of the city, state, or nation to 
protect us from certain types of environmental 
hazards.  But in the future there may be attempts 
to shift that responsibility to individuals who are 
known to be unusually susceptible to a certain 
type of environmental stress. Or the 
environmental regulation standards could be 
changed in such a way that highly susceptible 
individuals would not be protected from specific 
hazards. As a society, how far do we go in 
making such protection of susceptible 
individuals a civic responsibility? 
 
As we develop new policies addressing these 
issues and concerns, “how much is enough?” 
This is the standard, old-fashioned question, and 
the question about the role of the precautionary 
principle that we deal with in the environmental 
field. How do we know when we have enough 
information in order to act to create a policy? 
How do we achieve agreement so that public 
officials can successfully develop and 
implement policies? And, do we have 
mechanisms in place to meet these policy needs? 
I believe this area of “policy science” 
surrounding gene-environment interaction 
research is going to be one of the most important 
fields in the next ten to twenty years, and 
probably beyond. For those of you interested in 
public policy, especially policy as it relates to 
human health and disease, there is a lot of work 
to do in the area, with a lot of very interesting 
and important questions to address. 
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